Group 1 - The company, Saito Bio, announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 0.1 RMB per 10 shares to all shareholders [2] - The record date for the dividend distribution is set for September 23, 2025, while the ex-dividend date is September 24, 2025 [2]

证券代码：300583 证券简称：赛托生物 公告编号：2025-037 山东赛托生物科技股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）2025 年半年度权益分 派方案已获 2025 年 9 月 12 日召开的 2025 年第一次临时股东大会审议通过，现将 权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司 2025 年第一次临时股东大会审议通过分配方案：公司以 189,702,126 股为基数，向全体股东每 10 股派发现金股利人民币 0.1 元（含税），共计派发现 金红利 1,897,021.26 元（含税），本次利润分配不送红股，不以资本公积金转增 股本，剩余未分配利润结转至以后年度分配。自董事会审议利润分配预案之日起 至实施方案的股权登记日期间，若公司股本因股权激励行权、可转债转股、股份 回购等情况发生变动，将按照分配总额不变的原则，对分配比例进行调整。 2、自分配方案披露至实施期间公司股本总数未发生变化； 二、本次实施的利润分配方案 2 ...

Core Viewpoint - The company, Saito Bio, announced the election of Ms. Li Lu as the employee representative director of the fourth board of directors during the first employee representative meeting of 2025, which will last until the end of the board's term [2]. Group 1 - The first employee representative meeting of 2025 is scheduled for September 12, 2025, at the company's administrative building [2]. - Ms. Li Lu was elected as the employee representative director of the fourth board of directors [2]. - The term for Ms. Li Lu will commence from the date of approval at the employee representative meeting until the end of the fourth board's term [2].

山东赛托生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日在公司行政大楼西办公楼会议室召开公司 2025 年第一次职工代表大会，审议 通过《关于选举李璐女士为第四届董事会职工代表董事的议案》。 经与会职工代表审议，一致同意选举李璐女士（简历详见附件）为公司第四 届董事会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第四届 董事会任期届满之日止。 李璐女士原为公司第四届董事会董事，本次选举完成后，变更为公司第四届 董事会职工代表董事，公司第四届董事会构成人员不变。 本次选举完成后，公司董事会中兼任公司高级管理人员职务的董事以及由职 工代表担任的董事，总计未超过公司董事总数的二分之一。 证券代码：300583 证券简称：赛托生物 公告编号：2025-036 山东赛托生物科技股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司章程指引》等法律法规和规范性 文件及《山东赛托生 ...

法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号楼 邮编：310008 国浩律师（杭州）事务所 关 于 山东赛托生物科技股份有限公司 2025 年第一次临时股东大会 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年九月 赛托生物 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 山东赛托生物科技股份有限公司 2025 年第一次临时股东大会 法律意见书 致：山东赛托生物科技股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受山东赛托生物科技股份 有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 ...

2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：300583 证券简称：赛托生物 公告编号：2025-035 山东赛托生物科技股份有限公司 特别提示： 1、本次股东大会不存在否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 山东赛托生物科技股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会会议通知于 2025 年 8 月 26 日以公告形式发出，本次股东大会采取现场投 票和网络投票相结合的方式召开。其中，现场会议于 2025 年 9 月 12 日（星期五） 14:30 在公司会议室召开；通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 9 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00。通过深圳证券交易所 互联网系统投票的具体时间为 2025 年 9 月 12 日 9:15-15:00。 本次会议由公司董事会召集，米奇先生主持，公司全体董事、监事、高级管 理人员和见证律师等出席或列席会议。 ...

Group 1 - The company, Saito Bio (300583.SZ), stated on the interactive platform that it currently does not have any formulations suitable for hepatitis [1]

Group 1 - The stock of Saito Bio (300583.SZ) closed at 16.39 yuan, with a decline of 3.87%, resulting in a total market capitalization of 3.109 billion yuan [1] - Saito Bio is currently in a state of breaking its initial public offering price, having been listed on the ChiNext board on January 6, 2017, with an initial offering price of 40.29 yuan per share [1] - The company raised a total of 1.0744 billion yuan through its initial public offering, with a net amount of 1.0256 billion yuan after deducting issuance costs [1][3] Group 2 - Saito Bio has conducted a non-public issuance of 11.6418 million shares at a price of 22.47 yuan per share, raising a total of 261.5904 million yuan [2] - After deducting underwriting and sponsorship fees of 7.8 million yuan, the net amount raised from this issuance was 251.9224 million yuan [2] - The total amount raised by Saito Bio since its listing amounts to 1.336 billion yuan [3]

Core Insights - The financial report of Saito Bio (300583) for the first half of 2025 shows a significant decline in net profit, down 498.8% year-on-year, with total revenue also decreasing by 10.39% [1] Financial Performance Summary - Total revenue for the first half of 2025 was 508 million yuan, a decrease from 567 million yuan in the same period of 2024, representing a decline of 10.39% [1] - The net profit attributable to shareholders was -52.69 million yuan, compared to a profit of 13.21 million yuan in the previous year, marking a decline of 498.8% [1] - The gross profit margin fell to 12.01%, down 53.45% year-on-year, while the net profit margin turned negative at -11.78%, a decrease of 614.8% [1] - Selling, administrative, and financial expenses totaled 68.58 million yuan, accounting for 13.51% of revenue, which is an 18.83% decrease from the previous year [1] - Earnings per share dropped to -0.28 yuan, a decline of 500% compared to the previous year [1] Changes in Financial Items - Right-of-use assets decreased by 84.9% due to a reduction in operating lease real estate business [3] - Lease liabilities saw a decline of 93.32%, also attributed to the decrease in operating lease real estate [3] - Other receivables decreased by 40.13% due to the timely recovery of export tax refunds [3] - Long-term deferred expenses were fully amortized, resulting in a 100% decrease [3] - Sales expenses decreased by 37.45% due to a reduction in the scope of consolidation following the sale of a foreign subsidiary [3] - Management expenses decreased by 32.13% due to both the sale of a foreign subsidiary and optimization of management processes [3] - Income tax expenses decreased by 60.99% due to a reduction in taxable income [3] Cash Flow and Debt Analysis - Net cash increase from cash and cash equivalents rose by 469.23%, driven by increased cash flow from financing activities [4] - The company has a cash flow situation that warrants attention, with cash and cash equivalents to current liabilities at only 32.36% [5] - The interest-bearing debt ratio has reached 26.27%, indicating a significant level of debt [5]

Core Viewpoint - Saito Bio (300583.SZ) released its semi-annual report for 2025, indicating a stable increase in institutional investor holdings, reflecting growing confidence in the company [1] Group 1: Institutional Holdings - As of August 25, 2025, three institutional investors disclosed holdings in Saito Bio A-shares, totaling 43.3048 million shares, which represents 22.83% of the total share capital [1] - The institutional investors include Shandong Runxin Investment Co., Ltd., Huaan CSI 1000 Index Enhanced A, and Huaan CSI 500 Index Enhanced A [1] - Compared to the previous quarter, the total institutional holding percentage increased by 0.01 percentage points [1] Group 2: Public Fund Disclosures - During this period, two new public funds were disclosed compared to the previous quarter, namely Huaan CSI 1000 Index Enhanced A and Huaan CSI 500 Index Enhanced A [1]